Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Stem Cell Reports. 2018 Mar 13;10(3):933-941. doi: 10.1016/j.stemcr.2018.01.029. Epub 2018 Mar 1.
Allogeneic mesenchymal stem/stromal cells (MSCs) have been widely studied as an alternative cell source for regenerative medicine. Here, we report a long-term follow-up study of allogeneic bone marrow and/or umbilical cord MSC transplantation (MSCT) in severe and drug-refractory systemic lupus erythematosus (SLE) patients. Eighty-one patients were enrolled, and the 5-year overall survival rate was 84% (68/81) after MSCT. At 5-year follow-up, 27% of patients (22/81) were in complete clinical remission and another 7% (6/81) were in partial clinical remission, with a 5-year disease remission rate of 34% (28/81). In total, 37 patients had achieved clinical remission and then 9 patients subsequently relapsed, with 5-year overall rate of relapse of 24% (9/37). SLE Disease Activity Index scores, serum albumin, complement C3, peripheral white blood cell, and platelet numbers, as well as proteinuria levels, continued to improve during the follow-up. Our results demonstrated that allogeneic MSCT is safe and resulted in long-term clinical remission in SLE patients.
同种异体间充质干细胞（MSCs）已被广泛研究作为再生医学的替代细胞来源。在这里，我们报告了一项对严重和药物难治性系统性红斑狼疮（SLE）患者进行同种异体骨髓和/或脐带 MSC 移植（MSCT）的长期随访研究。共纳入 81 例患者，MSCT 后 5 年总生存率为 84%（68/81）。在 5 年随访时，27%（22/81）的患者达到完全临床缓解，另有 7%（6/81）达到部分临床缓解，5 年疾病缓解率为 34%（28/81）。共有 37 例患者达到临床缓解，随后 9 例患者复发，5 年总复发率为 24%（9/37）。SLE 疾病活动指数评分、血清白蛋白、补体 C3、外周白细胞和血小板计数以及蛋白尿水平在随访期间持续改善。我们的结果表明，同种异体 MSCT 是安全的，并导致 SLE 患者长期临床缓解。
